The Over-Diagnosis Paradox

Better technology does not always reveal a clearer picture of health. Sometimes, it merely gives a name to things that were never trying to hurt us.

Modern imaging tools like high-resolution helical CT scans and multi-parametric MRIs possess an almost microscopic curiosity. They spot tiny, slow-growing, indolent lesions that would have remained entirely harmless and asymptomatic across a person's natural life. This happens with routine mammography, PSA screenings for prostate cancer, and thyroid checks. In South Korea, a national thyroid screening program introduced in 1999 caused a fifteen-fold increase in diagnosed thyroid cancer incidence. Yet, the mortality rate didn't budge.

When harmless biological anomalies are rebranded as diseases, a mechanical cascade follows. Healthy people become lifelong patients, immediately subjected to invasive biopsies, radiation, and radical surgery. For prostate cancer, widespread PSA screening led to a thirty to fifty percent overdiagnosis rate, leaving countless individuals to suffer unnecessary treatments and side effects like incontinence or impotence without any real change in disease-specific mortality. The psychological toll of suddenly wearing a cancer label can be just as heavy as the physical interventions.

This creates a strange mathematical magic trick. Overdiagnosis inflates apparent survival rates through lead-time bias and length-time bias, manufacturing the illusion of major therapeutic breakthroughs. Survival statistics improve simply because healthier, non-progressive cases are dumped into the cohort, even though no actual life was prolonged.

Doctors still cannot predict at a molecular level which micro-tumors will stay dormant forever and which might eventually turn dangerous. But the rush to name everything we can see has created a paradoxical new rule of modern medicine: sometimes, the surest way to manufacture a patient is to look too closely.